SCHEMBL757253

SCHEMBL757253

N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 6/20 0.68
REN P00797 4/20 0.68
DPP4 P27487 3/20 0.64
KDM4E B2RXH2 1/20 0.55
F2 P00734 1/20 0.55
LMNA P02545 1/20 0.55
LTA4H P09960 1/20 0.55
MAPT P10636 1/20 0.55
PEPD P12955 1/20 0.55
ALOX15 P16050 1/20 0.55
PTGS1 P23219 1/20 0.55
HTR2A P28223 1/20 0.55
PTGS2 P35354 1/20 0.55
HRH1 P35367 1/20 0.55
THPO P40225 1/20 0.55
PMP22 Q01453 1/20 0.55
HSD17B10 Q99714 1/20 0.55
ACE2 Q9BYF1 1/20 0.55
FAP Q12884 1/20 0.47
DPP8 Q6V1X1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28776343 1.00 ACE (0.68) ACERENDPP4KDM4EF2
SCHEMBL757254 1.00 ACE (0.68) ACERENDPP4KDM4EF2
SCHEMBL7293351 0.89 ACE (0.57) ACERENDPP4KDM4EF2
SCHEMBL26429410 0.89 DPP4 (0.62) ACERENDPP4KDM4EF2
SCHEMBL7293358 0.89 ACE (0.57) ACERENDPP4KDM4EF2
SCHEMBL12343758 0.88 DPP4 (0.61) ACERENDPP4KDM4EF2
SCHEMBL30356637 0.86 ACE (0.59) ACERENDPP4KDM4EF2
SCHEMBL30938247 0.86 ACE (0.54) ACERENDPP4KDM4EF2
SCHEMBL2739551 0.85 ACE (0.56) ACERENDPP4KDM4EF2
SCHEMBL29405754 0.85 ACE (0.56) ACERENDPP4KDM4EF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743479-A1 ADENOVIRUSES Theolytics Ltd. (GB) 2026-05-20 EP claimed
EP-4743101-A1 MUTATED ADENOVIRUSES WITH IMPROVED REPLICATION AND THEIR USE FOR TREATING CANCER Theolytics Ltd. (GB) 2026-05-20 EP claimed
WO-2025245244-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR MODULATING WEIGHT LOSS ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245252-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR USE IN PAIN MANAGEMENT AND/OR SUBSTANCE USE DISORDERS ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245279-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245258-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONIST ANALOGS FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245292-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT LOSS ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245294-A1 NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025245288-A1 NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF ENDEVICA BIO, INC. (US) 2025-11-27 WO claimed
WO-2025123056-A1 NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS ENDEVICA BIO, INC. (US) 2025-06-12 WO claimed
CN-115894657-A Umami peptide and application thereof 江苏兴野食品有限公司 2023-04-04 CN claimed
EP-4125993-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING AMPHIPHILIC PEPTIDES AND METHODS OF USE THEREOF Bone Sci. Bio Ltd. (IL) 2023-02-08 EP claimed
WO-2023277549-A1 PEPTIDE COMPOUNDS FOR FLAVOR MODULATING 씨제이제일제당 (주) 2023-01-05 WO claimed
WO-2022201146-A1 DERMATOLOGICAL COMPOSITIONS AND USE THEREOF BONE SCI. BIO LTD. (IL) 2022-09-29 WO claimed
CN-108779152-B Insoluble fusion protein comprising antimicrobial peptide and method for producing antimicrobial peptide using same 建国大学校产学协力团 2022-08-26 CN claimed
US-20220227813-A1 Ras INHIBITORY PEPTIDE ICHIMARU PHARCOS CO., LTD. (JP) 2022-07-21 US claimed
EP-3970801-A1 RAS INHIBITORY PEPTIDE Ichimaru Pharcos Co., Ltd. (JP) 2022-03-23 EP claimed
US-11230575-B2 Insoluble fusion protein comprising antimicrobial peptide and method for producing antimicrobial peptide using same KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (KR) 2022-01-25 US claimed
EP-2032595-A1 PEPTIDE SUBSTANCE REVEALING AN IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION Obschestvo S Ogranichennoi Otvetstvennostyu "sia Peptides" (RU) 2009-03-11 EP claimed
WO-2007139435-A1 PEPTIDE SUBSTANCE REVEALING AN IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION OBSCHESTVO S OGRANICHENNOI OTVETSVENNOSTYU 'SIA PEPTIDES' (RU) 2007-12-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220227813-A1 Ras INHIBITORY PEPTIDE RSU1, RASGRP1, RASSF5 ACE 1638/4885REN 224/4885DPP4 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.